NAFDAC Raises Alarm Over ‘Hazardous’ G Fuel Energy Drink

In a recent public announcement, the National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a stern warning regarding the consumption of G Fuel brand Energy Drinks due to alarmingly high levels of caffeine.

The said energy drink, produced by T&E Imports and GPAE Trading Corp, is already facing recalls in various countries owing to its caffeine content, which has been deemed hazardous. Notably, the Netherlands Food and Consumer Product Safety Authority (NVWA) and the Canadian Food Inspection Agency (CFIA) have banned products with similar caffeine levels.

NAFDAC’s Director-General, Prof Mojisola Adeyeye, has expressed deep concern over the situation, indicating that the product’s consumption can lead to adverse health effects such as headaches, insomnia, irritability, and nervousness, primarily due to the excessive caffeine content. Even individuals sensitive to caffeine may experience these effects at remarkably low consumption levels.

Adeyeye further cautioned that pregnant women should steer clear of these products, as excessive caffeine intake could potentially result in miscarriages and low birth weight. She also highlighted the absence of cautionary statements on the affected products, leaving consumers unaware of the risks. Notably, these products are available for sale online.

It’s important to note that the G Fuel Energy Drink is not registered with NAFDAC, prompting the agency to strongly advise consumers and retailers against the use, sale, service, or distribution of the implicated product.

NAFDAC urges the public to report any suspicions regarding the distribution and sale of questionable packaged food products to the nearest NAFDAC office. They can be reached via the hotline 0800-162-3322 or by email at sf.alert@nafdac.gov.ng.

Additionally, healthcare professionals and patients are encouraged to report any adverse events or side effects related to the use of substandard NAFDAC-regulated products. This can be done at the nearest NAFDAC office, or through the E-reporting platforms available on the NAFDAC website (www.nafdac.gov.ng) and the Med-safety application downloadable on Android and IOS stores.

For further inquiries, NAFDAC can also be reached via email at pharmacovigilance@nafdac.gov.ng.

The safety of the public remains a top priority for NAFDAC as they take swift action against potential health hazards.